Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0063893
Title: Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome
Authors: Distrutti E.
Cipriani S.
Mencarelli A. 
Renga B.
Fiorucci S.
Keywords: placebo
VSL3
allodynia
analgesic activity
animal experiment
animal model
animal tissue
article
BDRKRB1 gene
CCL2 gene
CCR2 gene
CNR1 gene
controlled study
gene
gene expression
hyperalgesia
IL 10 gene
inflammation
irritable colon
male
maternal deprivation
microarray analysis
mouse
nociception
nonhuman
NOS3 gene
NTRK1 gene
OPRL1 gene
real time polymerase chain reaction
THP1 gene
TNFRSF1B gene
Trpv4 gene
upregulation
visceral pain
withdrawal reflex
Animals
Base Sequence
Disease Models, Animal
DNA Primers
Irritable Bowel Syndrome
Male
Mice
Placebos
Probiotics
Rats
Rats, Wistar
Real-Time Polymerase Chain Reaction
Visceral Pain
Issue Date: 2013
Citation: Distrutti E., Cipriani S., Mencarelli A., Renga B., Fiorucci S. (2013). Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome. PLoS ONE 8 (5) : e63893. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0063893
Rights: Attribution 4.0 International
Abstract: Background and Aims:Irritable bowel syndrome (IBS) is linked to post-inflammatory and stress-correlated factors that cause changes in the perception of visceral events. Probiotic bacteria may be effective in treating IBS symptoms. Here, we have investigated whether early life administration of VSL#3, a mixture of 8 probiotic bacteria strains, protects against development of visceral hypersensitivity driven by neonatal maternal separation (NMS), a rat model of IBS.Methods:Male NMS pups were treated orally with placebo or VSL#3 from days 3 to 60, while normal, not separated rats were used as controls. After 60 days from birth, perception of painful sensation induced by colorectal distension (CRD) was measured by assessing the abdominal withdrawal reflex (score 0-4). The colonic gene expression was assessed by using the Agilent Whole Rat Genome Oligo Microarrays platform and confirmed by real time PCR.Results:NMS rats exhibited both hyperalgesia and allodynia when compared to control rats. VSL#3 had a potent analgesic effect on CRD-induced pain without changing the colorectal compliance. The microarray analysis demonstrated that NMS induces a robust change in the expression of subsets of genes (CCL2, NOS3, THP1, NTRK1, CCR2, BDRKRB1, IL-10, TNFRSF1B, TRPV4, CNR1 and OPRL1) involved in pain transmission and inflammation. TPH1, tryptophan hydroxylase 1, a validated target gene in IBS treatment, was markedly upregulated by NMS and this effect was reversed by VSL#3 intervention.Conclusions:Early life administration of VSL#3 reduces visceral pain perception in a model of IBS and resets colonic expression of subsets of genes mediating pain and inflammation.Transcript profiling: Accession number of repository for expression microarray data is GSE38942 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE38942). © 2013 Distrutti et al.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/161318
ISSN: 19326203
DOI: 10.1371/journal.pone.0063893
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0063893.pdf1.95 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons